LCTX BioTime Inc.

0.95
+0.02  (+2%)
Previous Close 0.93
Open 0.95
Price To Book 1.07
Market Cap 142,041,004
Shares 149,642,861
Volume 242,989
Short Ratio 17.78
Av. Daily Volume 391,769
Stock charts supplied by TradingView

NewsSee all news

  1. Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

    Treatment with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company

  2. Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience's 49th Annual Scientific Meeting on October 23, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal

  3. Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa

  4. Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial

  5. Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans

    Sercader Ltd. Engaged to Identify European Commercial Partner Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data due 2019 and 2020.
VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 12-month data from cohorts 3 and 4 released July 31, 2018. Intends to meet with FDA regarding next steps.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 data presented at AAO October 14, 2019.
OpRegen
Dry age-related macular degeneration (AMD)

Latest News

  1. Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

    Treatment with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company

  2. Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience's 49th Annual Scientific Meeting on October 23, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal

  3. Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa

  4. Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial

  5. Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans

    Sercader Ltd. Engaged to Identify European Commercial Partner Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical

  6. Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  7. Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®

    Comparative clinical trial met its primary endpoint of change in hemifacial volume at six months (p<.001) Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company

  8. Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 4,000,000 shares of